A phase II study of gemcitabine concurrent with radiation in locally advanced squamous cell carcinoma of head and neck: A trial of the cancer research group Pakistan

Pakistan Journal of Medical Sciences

Volumn 22, Issue 3, 2006, Pages 258-264

  Shaharyar, ^a,b   Javed, Abrar Ahmed ^c   Shah, Ijaz Hussain ^d   Ansari, Tariq Nadeem ^e   Rasool, Shahid ^e   Faheem, Muhammad ^f   Mehmood, Humera ^f   Shah, Mazher Ali ^g   Khan, Muhammad Saleem ^h   Afridi, Muhammad Ali ^h  

^a MAYO HOSPITAL   (Pakistan)

^b Defence Housing Authority ^*  (Pakistan)

^c NISHTAR HOSPITAL   (Pakistan)

^d Allied Hospital Pakistan   (Pakistan)

^e National Institute of Heart Diseases National University of Medical Sciences   (Pakistan)

^f Institution Islamabad   (Pakistan)

^g SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL AND RESEARCH CENTRE   (Pakistan)

^h SHIFA INTERNATIONAL HOSPITAL   (Pakistan)

Author keywords

Gemcitabine; Head and Neck Cancer; Locally advanced squamous cell carcinoma; Radiotherapy

Indexed keywords

GEMCITABINE; RADIOSENSITIZING AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; FEMALE; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LARYNX CANCER; MALE; MEDICAL RESEARCH; MORBIDITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NASOPHARYNX CANCER; PAKISTAN; PHARYNX DISEASE; PHASE 2 CLINICAL TRIAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; SCORING SYSTEM; SKIN FISTULA; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS TISSUE; TIME SERIES ANALYSIS; TISSUE INJURY; WORLD HEALTH ORGANIZATION;

EID: 33748805541     PISSN: 1682024X     EISSN: 1682024X     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Schantz SP, Harrison LB, Forastiere AA. Tumours of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity and oropharynx. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, sixth edition, Philadelphia, Lippincott Willam and Wilkins 2001; 804-14.
2. Zakotnik B, Smid L, Budihna M, et al. Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: final report. Int J Radiat Oncol Biol Physics 1998; 41:121.
3. Merlano M, Benasso M, Corvo R, et al. Five year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of head and neck. J Natl Canc Inst 1996; 88(9):583.
4. Adenstein DJ, Adams GL, Li Y, et al. A phase II comparison of standard radiation therapy versus RT plus concurrent cisplatin versus split course RT plus concurrent DDP and 5 fllourouracil in patients with unresectable squamous cell head and neck cancer. Proc Am Soc Clin Oncol 2000; 19:411a.
5. Wendt TG, Grabenbauer GG, Rodel CM. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16:1318.
6. Brizel DM, Albers ME, Fisther SR. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 42:145.
7. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy as an adjunct to definitive locoregional treatment for head and neck squamous cell carcinoma: results of three meta-analysis using updated individual data. Lancet 2000; 355:949.
8. Sanchiz F, Milla A, Roner J. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and ncek cancer. Int J Radiat Oncol Biol Phys 1990; 19:1347.
9. Gupta NK, Pointon RCS, Wilkinson PM. A randomized clinical trial to compare radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin Radiol 1987; 38:575.
10. Shanta V, Krishnamurthi S. Combined bleomycin and radiation therapy in oral cancer. Clin Radiol 1980; 156:228.
11. Al-Sarraf M, leblanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998; 16:1310.
12. Fu KK, Phillips TL. Biologic rationale of combined radiotherapy and chemotherapy. Haemotol Oncol Clin North Am 1991; 5:737.
13. Vokes EE, Weichulbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumours. J Clin Oncol 1990; 8:911.
14. Rosenthal DI, Sinnard R, Kavanaugh DY, et al. Dose escalating 7 week continous infusion paclitaxel with concurrent once daily radiation therapy for locally advanced squamous carcinoma of head and neck: a phase I study. Am Soc Clin Oncol 1999; 18:397a.
15. Flood W, Lee DJ, Trotti A. Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin. Semin Radiat Oncol 1999; 2:64.
16. Steinberg L, Hassan M, Olmsted L. A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinoma. Sem Oncol 1997; 24 (suppl 19): s19-51.
17. Liebman J, Cook J, A Fisher. In vitro studies of Taxol as a radiation sensitizer in human tumor cells.. J Natl Cancer Inst 1994; 86:441-6.
18. Milas L, Hunter NR, Mason KA. Enhancement of tumor radioresponse of a murine mammory carcinoma by paclitaxel. Cancer Res 1994; 55:3506-10.
19. Milas L, Hunter NR, Mason KA. Role of Reoxygenation in induction of enhancement of tumor radioresponse by paclitaxol. Cancer Res 1995; 55: 3564-8.
20. Shewach DS, Hahm TM, Chang E. Metabolism of 2-2-Difluro-2-Deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancers Research 1994; 54:3218-23.
21. Lawrence TS, Chang EY, Hahn TM. Radio-sensitization of pancreatic cell by 2-2-Difluro-2-Deoxycytidine. In J Radiat Oncol Biol Phys 1996; 34:867-72.
22. Zhang XL, Yang SL, Ashamalla H, Rafla S. Gemcitabine induced radiosensitization of human breast cancer cells. Proc Am Soc Clin Oncol 1998; 17:A1732.
23. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine mediated radiosensitization. Sem Oncol 1997; 24(suppl 7): S7-24-S7-28.
24. Lawrence TS. Radiosensitizing nucleosides. Am Soc Clin Oncol 1999; 156.
25. Wildfang I, Roub M, Gunner SA, Issing PH et al: Low dose Gemcitabine with radiotherapy in advanced head and neck and thyroid tumors. A Phase II study. Proc Am Soc Clin Oncol 1999; 1550: 401a.
26. Eisbruch A, Shewach DS, Bradford CR. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation Study. J Clin Oncol 2001; 19(3): 792-9.
27. Sobin LH, Wittekind CH editors: TNM classification of malignant tumors fifth edition New York. Wiley Liss 1997; 17-43.
28. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting the results of cancer treatment. Cancer 1981; 47:207-14.
29. Cox JD, Stetz J and Pajek TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer. (EORTC). Int J Radiat Oncol Biol Phys 1995;31(5): 1314-6.
30. Wibault P, Bensamaine M, de Forni M. Intenisve concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: A phase II study of radiotherapy with cisplatin and continuous infusion fluororacil. J clin oncol 1996; 14:1192-200.
31. Wasserman TH, Chapman JD, Coleman CN, Kligerman MM: Chemical modifiers of radiation. In: Perez CA, Brady LW, Editors: Principles and Practice of Radiation Oncology third edition Philadelphia Lippincot-Raven 1998; 695.
32. Hoffman W, Belka C, Schmidburger H, et al: Radiotherapy and concomitant weekly 1 hour infusion of paclitaxel in treatment of head and neck cancer: Results from a phase I trial. Int J radiat oncol Biol Phys 1997; 38:691-6.
33. Tishler RB, Busse PM, Norris CM Jr. An initial experience using concurrent paclitaxel and radiation in treatment of head and neck malignancies. Int J radiat Oncol Biol Phys 1999; 43:1001-8.
34. Steinberg L, Hassan M, Olmsted L. A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck Squamous cell carcinoma Semin Oncol 1997; 24:S19-69.
35. Rosenthal D, Sinard RJ, Okani O. Seven week continuous infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer; A phase I study. Semin Oncol 1997; 24:S19-67.
36. Brizel DM, Elber ME, Fischer RS, et al. Hyper-fractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338:1798-1804.
37. Brizel DM, Wasserman TH, Hanke M. Phase III randomized trial of amifostane as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18:3339-45.
38. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of Amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Rad Oncol Biol Phys 2002; 52: 739-47.
39. Voks EE, Gregor A, Turrisi AT: Gemcitabine and radiation therapy for non small cell lung cancer. Semin Oncol 1998; 25:6-69.
40. McGuinn CJ, Smith DC, Szarea CE: A phase I study of Gemcitabine in combination with radiation therapy in patients with localised unresectable pancreatic cancer. Proc Am Soc Clin Oncol 1998; 17:264a.